Clinical Trial: Rivoceranib Plus Paclitaxel in Patients With Gastrointestinal Stromal Tumor
Study Status: NOT_YET_RECRUITING
Recruit Status: NOT_YET_RECRUITING
Condition: Gastrointestinal Stromal Tumors
Study Type: INTERVENTIONAL
Official Title: A Phase 2 Study of Paclitaxel Plus Rivoceranib in Patients With GIST With a High P-glycoprotein Expression After Failure With at Least Imatinib, Sunitinib and Regorafenib
Brief Summary:
The purpose of this study is to evaluate the efficacy and safety of rivoceranib and paclitaxel combination therapy in patients with P-glycoprotein overexpressing GIST who failed standard treatment with imatinib, sunitinib, and regorafenib.
Read more